IGC Pharma, Inc. (IGC) Stock Price

IGCStock

$0.31−27.04%52W

Market Cap$32.05M

P/E—

PEG Ratio—

Div yield—

Beta0.49

IGC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-0.78%

Price vs S&P 500 (4W)24.94%

VGM Score41.24

Book Value / Share (Quarterly)$0.06

P/TBV (Annual)11.25x

Revenue Growth (3Y)-1.52%

Cash Flow / Share (Quarterly)$-0.07

Price vs S&P 500 (YTD)-2.66%

Gross Margin (TTM)29.68%

Net Profit Margin (TTM)-552.11%

EPS (TTM)$-0.07

10-Day Avg Trading Volume1.14M

EPS Excl Extra (TTM)$-0.07

Revenue Growth (5Y)-0.70%

EPS (Annual)$-0.05

ROI (Annual)-54.86%

Gross Margin (Annual)34.18%

Net Profit Margin (5Y Avg)-1404.75%

Cash / Share (Quarterly)$0.00

Revenue Growth QoQ (YoY)-3.94%

ROA (Last FY)-42.69%

Revenue Growth TTM (YoY)-6.69%

EBITD / Share (TTM)$-0.11

ROE (5Y Avg)-97.20%

Operating Margin (TTM)-860.29%

Cash Flow / Share (Annual)$-0.06

P/B Ratio4.78x

P/B Ratio (Quarterly)3.99x

Net Income / Employee (Annual)$-59,200

EV / Revenue (TTM)25.25x

Net Interest Coverage (TTM)-58.67x

ROA (TTM)-71.60%

EV / EBITDA (TTM)9.42x

EPS Incl Extra (Annual)$-0.05

Current Ratio (Annual)0.83x

Quick Ratio (Quarterly)0.12x

3-Month Avg Trading Volume0.72M

52-Week Price Return-27.04%

Revenue / Employee (TTM)$16,900

Tangible BV / Share (Quarterly)$0.01

P/S Ratio (Annual)33.64x

Asset Turnover (Annual)0.09x

52-Week High$0.47

Operating Margin (5Y Avg)-1519.14%

EPS Excl Extra (Annual)$-0.05

CapEx CAGR (5Y)-16.30%

Tangible BV CAGR (5Y)-40.97%

26-Week Price Return11.15%

Quick Ratio (Annual)0.47x

13-Week Price Return7.01%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)0.40x

Enterprise Value$29.95M

Revenue / Share Growth (5Y)-14.46%

Asset Turnover (TTM)0.13x

Book Value / Share Growth (5Y)-35.25%

Revenue / Employee (Annual)$12,400

Inventory Turnover (Annual)0.45x

Pretax Margin (Annual)-477.10%

Cash / Share (Annual)$0.01

3-Month Return Std Dev48.77%

Gross Margin (5Y Avg)46.65%

Net Income / Employee (TTM)$-93,500

ROE (Last FY)-55.85%

Net Interest Coverage (Annual)-7.57x

EPS Basic Excl Extra (Annual)$-0.05

P/FCF (TTM)108.28x

Receivables Turnover (TTM)33.41x

Total Debt / Equity (Quarterly)0.15x

EPS Incl Extra (TTM)$-0.07

Receivables Turnover (Annual)34.82x

ROI (TTM)-90.20%

P/S Ratio (TTM)24.65x

Pretax Margin (5Y Avg)-1404.75%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$0.02

Price vs S&P 500 (52W)-45.60%

Year-to-Date Return10.16%

5-Day Price Return3.13%

EPS Normalized (Annual)$-0.05

ROA (5Y Avg)-75.67%

Net Profit Margin (Annual)-477.10%

Month-to-Date Return24.50%

Cash Flow / Share (TTM)$-0.19

EBITD / Share (Annual)$-0.08

Operating Margin (Annual)-891.25%

LT Debt / Equity (Annual)0.02x

ROI (5Y Avg)-95.63%

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$-0.07

P/TBV (Quarterly)28.63x

P/B Ratio (Annual)3.52x

Inventory Turnover (TTM)0.83x

Pretax Margin (TTM)-552.11%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)5.05%

Beta0.49x

Revenue / Share (TTM)$0.01

ROE (TTM)-94.51%

52-Week Low$0.23

vGradeD

gGradeD

mGradeC

vgmGradeC

IGC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$0.02	-$0.03	-50.00%(-$0.01)
Q1 2026	May 15, 2026	-$0.02	-$0.02	+0.00%(+$0.00)
Q1 2025	Jun 27, 2025	-$0.02	-$0.01	+50.00%(+$0.01)
Q4 2024	Feb 14, 2025	-$0.03	-$0.02	+33.33%(+$0.01)
Q3 2024	Nov 12, 2024	-$0.03	-$0.02	+33.33%(+$0.01)

IGC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
IGCIGC Pharma, Inc.	D	D	C	$0.31
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About IGC Pharma, Inc.

IGC Pharma develops cannabinoid-based therapeutics for neurological and pain disorders. The company's Alzheimer's disease program includes four investigational candidates (IGC-AD1, IGC-M3, IGC-1C, and TGR-63) that have demonstrated preclinical potential to reduce amyloid plaques and tau tangles. Additional pipeline programs target period cramps, premenstrual syndrome, and chronic pain.